Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 18/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 18/20 | 0.55 |
| ▸ | WNT1 | P04628 | 9/20 | 0.55 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | CLK3 | P49761 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23741019 | 0.95 | DYRK1A (0.52) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL23740820 | 0.91 | GSK3B (0.52) | GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL23741020 | 0.88 | DYRK1A (0.59) | GSK3BDYRK1AWNT1 | |
| SCHEMBL23741143 | 0.87 | DYRK1A (0.48) | GSK3BDYRK1AWNT1 | |
| SCHEMBL23740986 | 0.87 | GSK3B (0.58) | GSK3BDYRK1AWNT1 | |
| SCHEMBL23740732 | 0.86 | ABL1 (0.51) | GSK3BDYRK1AWNT1ABL1CLK2 | |
| SCHEMBL23741149 | 0.86 | DYRK1A (0.59) | GSK3BDYRK1AWNT1ABL1CLK2 | |
| SCHEMBL23740812 | 0.86 | DYRK1A (0.54) | GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL24219028 | 0.85 | DYRK1A (0.40) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL23741017 | 0.84 | GSK3B (0.55) | GSK3BDYRK1AWNT1ABL1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943086-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | BioSplice Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3448838-B1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2021-08-11 | — | — | EP | disclosed |